The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

MBX Biosciences, Inc.’s MBX share price has dipped by 14.00%, which has investors questioning if this is right time to buy.

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight ... by The BMJ today. Glucagon-like peptide 1 receptor agonists (GLP1RA ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, ...

In December 2024, the Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the ...